IL6 and neoplasm: Also, Mobilan (M-VM3), a recombinant adenovirus-based gene therapy, has shown tumor responses in early-stage prostate cancer through stimulation of TLR5 signaling and consequent immune activation following intra-prostatic injection, accompanied by temporary PSA and cytokine (G-CSF, IL-6) increases and greater lymphoid infiltration in prostate tissue, unlike in placebo patients.